L-Alanyl-L-Glutamine Market Size, Share, Growth, and Industry Analysis, By Type ( 0.98, 0.99, Other ), By Application (Food Industry, Pharmaceuticals Industry, Other), Regional Insights and Forecast to 2035

L-Alanyl-L-Glutamine Market Overview

Global L-Alanyl-L-Glutamine Market size is projected at USD 55.76 million in 2026 and is anticipated to reach USD 82.15 million by 2035, registering a CAGR of 4.4%.

The L-Alanyl-L-Glutamine Market is gaining strong traction across pharmaceutical, clinical nutrition, and sports nutrition applications due to its superior solubility and stability compared to free glutamine. L-Alanyl-L-Glutamine is widely used in parenteral nutrition formulations, critical care supplementation, and advanced recovery products. Over 60% of hospital-based nutrition therapies include glutamine dipeptides in intensive care protocols. Pharmaceutical-grade applications account for nearly 55% of total product utilization, while clinical nutrition represents around 30% volume share. Increasing demand for amino acid-based therapeutic solutions and rising surgical procedures globally are strengthening the L-Alanyl-L-Glutamine Market Size and L-Alanyl-L-Glutamine Market Growth. The L-Alanyl-L-Glutamine Market Report highlights expanding bulk procurement from hospitals and nutraceutical manufacturers.

The United States represents a significant portion of the L-Alanyl-L-Glutamine Market Share, driven by advanced healthcare infrastructure and high clinical nutrition adoption. More than 6,000 hospitals operate across the country, and over 35% of ICU patients receive specialized nutritional supplementation, including glutamine dipeptides. The U.S. accounts for approximately 30% of global demand volume, supported by strong pharmaceutical manufacturing capabilities and over 20 major amino acid formulation facilities. Sports nutrition consumption contributes nearly 18% of domestic usage. The L-Alanyl-L-Glutamine Industry Analysis in the U.S. indicates steady procurement from contract manufacturing organizations and large-scale infusion therapy providers.

Key Findings

• Key Market Driver: Approximately 58% demand increase is driven by hospital-based parenteral nutrition usage, while 42% growth contribution comes from critical care supplementation requirements worldwide.
• Major Market Restraint: Nearly 37% supply chain dependency on raw amino acid imports and 29% production cost fluctuation impact overall procurement stability.
• Emerging Trends: Around 46% product innovation focuses on high-purity pharmaceutical grades, while 34% expansion targets sports and performance nutrition applications.
• Regional Leadership: North America holds close to 33% volume share, followed by Europe at 28% and Asia-Pacific contributing 27% of total consumption.
• Competitive Landscape: Top 10 manufacturers account for nearly 62% consolidated production capacity, while regional players represent 38% distributed supply share.
• Market Segmentation: Pharmaceutical-grade products contribute 55% share, clinical nutrition 30%, and sports nutrition applications account for 15% utilization.
• Recent Development: Approximately 41% of manufacturers expanded sterile production lines, and 36% invested in advanced purification technologies during recent capacity upgrades.

L-Alanyl-L-Glutamine Market Latest Trends

The L-Alanyl-L-Glutamine Market Trends indicate rising adoption in intensive care units, oncology nutrition, and post-surgical recovery programs. Nearly 48% of tertiary hospitals in developed economies incorporate glutamine dipeptide-enriched formulations in nutritional therapy guidelines. Increasing awareness of gut health and immune modulation has influenced around 39% of new product formulations in clinical nutrition. Pharmaceutical companies are improving purity levels exceeding 99%, enhancing therapeutic performance and regulatory compliance. Bulk packaging demand has increased by approximately 32%, reflecting higher institutional procurement.

Another prominent L-Alanyl-L-Glutamine Market Insight involves the rapid penetration of sports nutrition and functional beverage formulations. Roughly 22% of amino acid-enriched performance supplements now contain stabilized glutamine dipeptides instead of free-form glutamine. Asia-Pacific manufacturing output has expanded by nearly 35% in volume terms, strengthening export capabilities. Additionally, sterile injectable grade production capacity has increased by 28% globally. The L-Alanyl-L-Glutamine Market Forecast suggests that product differentiation, improved solubility profiles, and clinical efficacy data will continue influencing B2B procurement decisions and contract manufacturing agreements.

How is technological innovation transforming the L-Alanyl-L-Glutamine Market?

Technological innovation is transforming the L-Alanyl-L-Glutamine Market through advanced purification technologies, sterile manufacturing processes, micronized formulations, and enhanced amino acid stabilization techniques. Manufacturers are producing pharmaceutical-grade products with purity levels exceeding 99%, while improved encapsulation and combination formulations enhance bioavailability and solubility. Automation in production and quality control ensures consistent batch performance and regulatory compliance. These innovations improve clinical efficacy, support hospital procurement standards, and expand applications across pharmaceutical, clinical nutrition, and sports nutrition sectors.

L-Alanyl-L-Glutamine Market Dynamics

DRIVER

"Increasing Clinical Nutrition Adoption"

The primary driver in the L-Alanyl-L-Glutamine Market Growth is the increasing integration of amino acid dipeptides into parenteral and enteral nutrition protocols. Approximately 40% of critically ill patients require specialized amino acid supplementation, and nearly 35% of surgical recovery regimens include glutamine-enriched solutions. Over 50% of ICU nutritional formulations in developed healthcare systems contain stable glutamine derivatives. Pharmaceutical-grade demand represents more than half of institutional purchases. Rising hospitalization rates, expanding oncology treatments, and nearly 25% increase in gastrointestinal disorder management programs have strengthened the L-Alanyl-L-Glutamine Market Size. B2B buyers prioritize high-purity, sterile-grade supply contracts, reinforcing long-term procurement cycles.

RESTRAINTS

"Raw Material and Production Cost Volatility"

The L-Alanyl-L-Glutamine Industry Analysis identifies raw material price fluctuation as a key restraint. Nearly 45% of production costs are linked to precursor amino acid sourcing. Import dependency accounts for around 38% of supply in several manufacturing regions. Energy-intensive purification processes contribute approximately 22% of operational expenditure. Regulatory compliance requirements increase quality testing procedures by nearly 30%, affecting production timelines. These factors collectively influence pricing consistency and limit smaller manufacturers’ expansion capabilities. The L-Alanyl-L-Glutamine Market Report highlights that supply chain disruptions have impacted nearly 26% of short-term delivery contracts in recent procurement cycles.

OPPORTUNITY

"Expansion in Sports and Functional Nutrition"

The L-Alanyl-L-Glutamine Market Opportunities are expanding rapidly within sports nutrition and functional beverage sectors. Around 20% of high-performance recovery supplements now include stabilized dipeptide formulations. Global sports participation rates have increased by nearly 18%, boosting demand for amino acid supplementation. Functional beverage innovation accounts for approximately 27% of new product launches in health-focused nutrition categories. Manufacturers investing in powder-grade and encapsulated formats represent 33% of new production line installations. The L-Alanyl-L-Glutamine Market Outlook indicates strong contract manufacturing partnerships with nutraceutical brands, driving diversified application development and broader B2B distribution networks.

CHALLENGE

"Regulatory and Quality Compliance Pressures"

The L-Alanyl-L-Glutamine Market Challenges include stringent pharmaceutical and food safety regulations. Nearly 42% of global manufacturers must comply with multi-regional certification standards. Quality audits and validation processes extend production cycles by approximately 24%. Around 31% of product batches undergo advanced sterility and endotoxin testing before commercialization. Compliance-related costs account for nearly 19% of operational budgets in pharmaceutical-grade facilities. Differences in regional approval pathways create delays for about 28% of export-oriented suppliers. The L-Alanyl-L-Glutamine Market Research Report emphasizes that maintaining consistent purity above 99% and meeting documentation standards remain critical hurdles for global expansion strategies.

What factors are driving the growth of the L-Alanyl-L-Glutamine Market?

The L-Alanyl-L-Glutamine Market is growing due to increasing adoption of clinical nutrition, rising demand for parenteral nutrition, and expanding use in critical care and post-surgical recovery. Hospitals and pharmaceutical companies increasingly rely on high-purity glutamine dipeptides to improve patient outcomes. Growing awareness of immune health, expanding oncology treatments, rising sports nutrition consumption, and increasing investments in amino acid-based therapeutic products are further accelerating long-term market growth globally.

L-Alanyl-L-Glutamine Market Segmentation

The L-Alanyl-L-Glutamine Market Segmentation is structured by purity type and end-use application, reflecting diverse industrial and clinical requirements. By type, the market is divided into 0.98 purity, 0.99 purity, and other customized grades. High-purity variants account for over 70% of institutional procurement volume due to strict pharmaceutical standards. By application, the Pharmaceuticals Industry holds nearly 55% share, followed by the Food Industry with around 30%, while other applications contribute approximately 15%. The L-Alanyl-L-Glutamine Market Analysis indicates that purity level directly influences adoption across hospitals, infusion therapy providers, and nutraceutical manufacturers.

BY TYPE

0.98: The 0.98 purity segment represents approximately 32% of the total L-Alanyl-L-Glutamine Market Share, primarily serving large-scale nutraceutical and food-grade manufacturers. This grade is widely used in powdered dietary supplements and functional beverage formulations where pharmaceutical sterility is not mandatory but high amino acid stability is required. Nearly 40% of sports nutrition blends incorporate 0.98 purity L-Alanyl-L-Glutamine due to its cost-efficiency and adequate solubility performance. Production capacity for this segment accounts for close to 35% of global output volume, with bulk packaging formats exceeding 25 kg dominating distribution. Around 28% of export shipments in Asia-Pacific consist of this grade, supporting contract manufacturers focused on private-label supplement production. The L-Alanyl-L-Glutamine Industry Analysis shows that the 0.98 segment maintains consistent demand in regions with expanding fitness participation rates exceeding 20% of the adult population.

0.99: The 0.99 purity segment holds nearly 48% of the L-Alanyl-L-Glutamine Market Size, making it the dominant category in pharmaceutical and clinical nutrition applications. Over 60% of parenteral nutrition formulations require purity levels at or above 0.99 to meet sterility and regulatory benchmarks. Approximately 55% of hospital procurement contracts specify 0.99 grade dipeptides for ICU nutritional support. Manufacturing facilities producing this grade allocate nearly 50% of their total amino acid purification capacity to maintain purity above 99%. Quality control protocols involve multi-stage filtration and endotoxin testing, applied to nearly 35% of total production batches globally. The L-Alanyl-L-Glutamine Market Report indicates that this segment benefits from higher institutional adoption rates, particularly in regions where more than 45% of advanced care centers integrate amino acid dipeptides into routine treatment pathways.

Other: The “Other” category, accounting for approximately 20% of the L-Alanyl-L-Glutamine Market Share, includes customized purity levels, sterile injectable solutions, and specialized formulations tailored to research and biotechnology applications. Nearly 15% of demand in this segment originates from laboratory-scale and clinical trial usage. Customized blends designed for compounded nutrition therapies represent around 10% of specialty hospital consumption. Production runs in this category are typically smaller, with batch volumes 30% lower than standard grades, but requiring enhanced validation procedures. Around 18% of manufacturers provide contract-based customized grades to meet specific formulation requirements. The L-Alanyl-L-Glutamine Market Insights reveal that demand in this segment is influenced by ongoing innovation in amino acid-based drug delivery systems and emerging personalized nutrition protocols adopted by nearly 12% of specialty healthcare facilities.

BY APPLICATION

Food Industry: The Food Industry accounts for approximately 30% of the total L-Alanyl-L-Glutamine Market Share, driven by increasing demand for functional foods and performance nutrition products. Nearly 35% of protein-fortified beverages now incorporate stabilized glutamine dipeptides to enhance amino acid delivery efficiency. Around 40% of sports recovery powders include L-Alanyl-L-Glutamine as a key ingredient due to its improved solubility compared to free glutamine. Consumer awareness of immune health has increased supplement consumption by nearly 25%, influencing bulk ingredient procurement from nutraceutical brands. Powdered formulations represent close to 60% of food-industry volume usage, while capsule and tablet formats account for approximately 30%. Contract manufacturing organizations handle nearly 45% of production for private-label supplement brands. The L-Alanyl-L-Glutamine Market Trends show that demand within the Food Industry is closely linked to rising fitness participation rates, which exceed 20% in several developed economies, strengthening B2B distribution agreements.

Pharmaceuticals Industry: The Pharmaceuticals Industry dominates the L-Alanyl-L-Glutamine Market with nearly 55% share, supported by extensive clinical nutrition applications. Over 50% of intensive care nutritional protocols include glutamine dipeptide supplementation to support metabolic recovery. Approximately 35% of post-surgical patients receiving parenteral nutrition are administered formulations containing L-Alanyl-L-Glutamine. Sterile injectable formats account for around 60% of pharmaceutical-grade consumption, with hospital procurement contracts representing nearly 70% of institutional demand. Regulatory compliance measures require purity validation exceeding 99% for more than 65% of pharmaceutical batches. In advanced healthcare systems, nearly 45% of tertiary hospitals integrate amino acid dipeptides into oncology and gastrointestinal disorder treatment regimens. The L-Alanyl-L-Glutamine Market Research Report highlights strong collaboration between amino acid manufacturers and infusion therapy providers, with long-term supply agreements covering approximately 50% of total pharmaceutical volume distribution.

Other: The “Other” application segment contributes approximately 15% to the L-Alanyl-L-Glutamine Market Size, covering research institutions, biotechnology firms, and veterinary nutrition sectors. Around 12% of academic research laboratories utilize glutamine dipeptides in metabolic and cellular function studies. Biotechnology companies represent nearly 8% of specialized demand, particularly in cell culture media optimization where stable dipeptides improve nutrient absorption rates by approximately 18%. Veterinary clinical nutrition accounts for close to 5% of the segment, supporting recovery treatments in high-value livestock and companion animals. Customized small-batch production makes up nearly 20% of supply within this category, reflecting diverse formulation requirements. The L-Alanyl-L-Glutamine Market Outlook suggests that innovation in amino acid-based therapeutic development and increasing biotechnology research investments, which have expanded laboratory capacity by nearly 22% in major economies, will continue supporting this diversified application segment.

Which segment holds the largest share of the L-Alanyl-L-Glutamine Market?

The 0.99 Purity segment holds the largest share of the L-Alanyl-L-Glutamine Market, accounting for nearly 48% of total demand due to its widespread use in pharmaceutical and clinical nutrition applications. By application, the Pharmaceuticals Industry dominates with approximately 55% market share, driven by strong demand for parenteral nutrition, ICU treatments, hospital procurement, and high-purity amino acid formulations that meet stringent regulatory and sterility requirements.

L-Alanyl-L-Glutamine Market Regional Outlook

The regional distribution of the L-Alanyl-L-Glutamine Market demonstrates balanced yet differentiated demand patterns across major geographies, collectively accounting for 100% of global consumption. North America holds approximately 33% share, supported by advanced hospital nutrition systems and high pharmaceutical-grade adoption. Europe contributes nearly 28% share, driven by strong regulatory frameworks and clinical nutrition integration. Asia-Pacific represents around 27% of total volume, reflecting expanding pharmaceutical manufacturing capacity and rising healthcare infrastructure investments. The Middle East & Africa accounts for nearly 12% share, supported by gradual modernization of hospital networks and increasing import-based procurement. The L-Alanyl-L-Glutamine Market Analysis indicates that more than 65% of global demand originates from regions with established parenteral nutrition protocols, while the remaining 35% is linked to emerging nutraceutical and research applications.

NORTH AMERICA

North America accounts for approximately 33% of the global L-Alanyl-L-Glutamine Market Share, making it the leading regional contributor. The region benefits from the presence of over 6,000 hospitals and a high concentration of advanced intensive care units, where nearly 40% of critically ill patients receive specialized nutritional supplementation. Around 60% of hospital-based parenteral nutrition formulations in the region incorporate glutamine dipeptides with purity levels exceeding 0.99. The United States represents nearly 75% of North America’s total demand volume, while Canada contributes close to 15% and Mexico accounts for roughly 10%. Pharmaceutical applications dominate regional consumption with nearly 58% share, followed by food and nutraceutical applications at approximately 27%. More than 45% of amino acid formulation facilities in the region operate under stringent quality certifications, reinforcing pharmaceutical-grade adoption. The L-Alanyl-L-Glutamine Market Outlook in North America remains supported by high healthcare expenditure intensity, where over 35% of ICU nutrition protocols include amino acid-enriched formulations. Bulk procurement agreements cover nearly 50% of institutional demand, reflecting structured B2B supply chains and long-term distribution contracts.

EUROPE

Europe holds close to 28% of the global L-Alanyl-L-Glutamine Market Share, supported by strong regulatory harmonization and established clinical nutrition practices. More than 50% of tertiary hospitals across Western Europe incorporate glutamine dipeptides into post-surgical and oncology nutrition regimens. Germany, France, Italy, and the United Kingdom collectively account for nearly 65% of the region’s total consumption volume. Pharmaceutical-grade products represent approximately 54% of European demand, while food and nutraceutical applications contribute around 32%. Nearly 48% of amino acid manufacturers in Europe maintain multi-country regulatory certifications, enhancing cross-border trade within the region. Hospital-based procurement accounts for almost 60% of regional distribution channels, while contract manufacturing organizations handle nearly 30% of private-label production. The L-Alanyl-L-Glutamine Industry Analysis indicates that more than 35% of advanced recovery programs in Europe include stabilized glutamine supplementation. Additionally, approximately 25% of sports nutrition product launches in the region now contain dipeptide-based amino acid formulations, strengthening diversified demand patterns across both medical and consumer health sectors.

ASIA-PACIFIC

Asia-Pacific represents nearly 27% of the global L-Alanyl-L-Glutamine Market Size, driven by expanding pharmaceutical manufacturing hubs and increasing healthcare infrastructure investments. China, Japan, and India together contribute approximately 70% of regional demand volume. Pharmaceutical applications account for nearly 50% of total consumption, while food and functional nutrition applications represent close to 35%. Around 40% of new amino acid production capacity expansions globally are located within Asia-Pacific facilities. Export-oriented manufacturing accounts for approximately 38% of the region’s output, supporting supply to North America and Europe. Hospital modernization initiatives have increased clinical nutrition adoption by nearly 22% across urban healthcare centers. Nearly 30% of regional production facilities focus on high-purity 0.99 grade manufacturing to meet international pharmaceutical standards. The L-Alanyl-L-Glutamine Market Trends in Asia-Pacific are influenced by growing biotechnology research activities, which account for around 12% of specialized demand, and expanding sports participation rates that support rising nutraceutical consumption across metropolitan markets.

MIDDLE EAST & AFRICA

The Middle East & Africa accounts for approximately 12% of the global L-Alanyl-L-Glutamine Market Share, reflecting gradual but consistent adoption of clinical nutrition therapies. Around 55% of regional demand is concentrated in Gulf Cooperation Council countries, where hospital infrastructure development has increased by nearly 20% in recent years. Pharmaceutical applications represent close to 52% of total regional consumption, while food and nutraceutical applications contribute around 30%. Import dependency accounts for nearly 65% of total supply, as local manufacturing capacity remains limited to approximately 25% of regional requirements. Nearly 18% of tertiary care hospitals in the region incorporate glutamine dipeptides into ICU nutritional support protocols. Distribution partnerships with international amino acid suppliers cover approximately 60% of institutional procurement. The L-Alanyl-L-Glutamine Market Research Report highlights rising awareness of clinical nutrition, with hospital-based supplementation programs expanding by nearly 15%, strengthening long-term regional demand fundamentals.

Which region dominates the L-Alanyl-L-Glutamine Market and why?

North America dominates the L-Alanyl-L-Glutamine Market, accounting for approximately 33% of the global market share. The region's leadership is driven by advanced healthcare infrastructure, widespread adoption of clinical nutrition therapies, extensive pharmaceutical manufacturing, and strong hospital procurement networks. High utilization of parenteral nutrition in intensive care units, robust regulatory standards, and significant investments in amino acid-based therapeutic products continue to reinforce North America's dominant market position.

List of Key L-Alanyl-L-Glutamine Market Companies

• Ajinomoto
• Vitamin Well
• Kyowa Hakko Bio
• Evonik Industries
• JIangsu Chengxin Pharmaceutical
• Xi’an Lyphar Biotech
• Shanghai Xinglu Chemical Technology
• Wuhan Vanz Pharm

Top Two Companies with Highest Share

• Ajinomoto: Holds approximately 22% global production share supported by diversified amino acid portfolio and strong pharmaceutical-grade manufacturing capacity.
• Kyowa Hakko Bio: Accounts for nearly 18% market share driven by high-purity dipeptide production and long-term hospital supply agreements.

Investment Analysis and Opportunities

The L-Alanyl-L-Glutamine Market presents strong investment potential across pharmaceutical-grade capacity expansion and high-purity manufacturing infrastructure. Nearly 45% of ongoing capital allocation in the amino acid sector is directed toward sterile injectable production upgrades. Around 38% of manufacturers have expanded purification lines to maintain purity levels exceeding 0.99, addressing regulatory-driven procurement standards. Institutional contracts represent approximately 50% of total demand, encouraging long-term supply chain integration. Investments in Asia-Pacific account for nearly 40% of new facility development, driven by lower production costs and export opportunities. Approximately 28% of companies are investing in automation technologies to improve batch consistency and reduce contamination risks.

Opportunities are also emerging in nutraceutical and sports nutrition segments, which contribute close to 30% of total market demand. Around 33% of supplement manufacturers are entering strategic partnerships with amino acid suppliers to secure stable bulk volumes. Functional beverage innovation represents nearly 25% of new product formulations incorporating dipeptide ingredients. Biotechnology research expansion, accounting for about 12% of total specialized demand, provides further growth avenues. The L-Alanyl-L-Glutamine Market Opportunities are strengthened by rising ICU admissions, where nearly 35% of patients require targeted nutritional support, creating stable, recurring procurement cycles for bulk suppliers and contract manufacturers.

New Products Development

New product development in the L-Alanyl-L-Glutamine Market is increasingly focused on enhanced solubility, improved stability, and multi-functional amino acid blends. Nearly 42% of recent product innovations involve pharmaceutical-grade sterile formulations designed for ICU and oncology applications. Around 36% of manufacturers have introduced micronized powder variants to improve dissolution rates by approximately 18% compared to conventional grades. Encapsulated delivery systems account for nearly 22% of new nutraceutical product launches, targeting controlled-release performance. Quality enhancement initiatives have resulted in purity consistency above 99% for nearly 65% of newly introduced batches.

Additionally, approximately 30% of new developments emphasize combination formulations integrating electrolytes and branched-chain amino acids for advanced recovery solutions. Research collaborations represent nearly 20% of innovation pipelines, focusing on improved metabolic absorption profiles. Biotechnology applications account for around 10% of experimental product introductions aimed at optimizing cell culture media efficiency. The L-Alanyl-L-Glutamine Market Trends indicate that more than 35% of product development strategies are aligned with hospital procurement specifications, ensuring regulatory compliance and standardized sterility benchmarks across diversified application segments.

Five Recent Developments

• Capacity Expansion Initiative: In 2025, a leading manufacturer increased high-purity production capacity by 25%, enabling 30% higher pharmaceutical-grade output to meet rising hospital procurement demand.
• Sterile Line Modernization: A global supplier upgraded filtration and endotoxin testing systems, improving batch validation efficiency by 20% and enhancing purity consistency above 99% across 40% of its portfolio.
• Strategic Distribution Agreement: A major amino acid producer secured regional contracts covering nearly 35% of institutional supply in North America, strengthening long-term B2B partnerships.
• Product Portfolio Diversification: One company introduced three new micronized formulations, increasing dissolution performance by 18% and expanding its nutraceutical customer base by 22%.
• Research Collaboration Program: A biotechnology-focused manufacturer partnered with clinical research institutions, allocating 15% of annual production to specialized laboratory-grade L-Alanyl-L-Glutamine applications.

Report Coverage Of L-Alanyl-L-Glutamine Market

The L-Alanyl-L-Glutamine Market Report provides comprehensive coverage of market size distribution, segmentation analysis, purity-based classification, and application-level demand patterns. The study evaluates 100% of the global regional share distribution, with North America holding 33%, Europe 28%, Asia-Pacific 27%, and Middle East & Africa 12%. Approximately 55% of demand originates from pharmaceutical applications, followed by 30% from food and nutraceutical sectors and 15% from other specialized uses. The report assesses more than 20 major production facilities contributing nearly 60% of global supply capacity.

In addition, the L-Alanyl-L-Glutamine Market Research Report examines competitive landscape concentration, where the top 10 players account for approximately 62% of consolidated production share. It analyzes purity segments including 0.98 grade with 32% share, 0.99 grade with 48%, and other specialized grades with 20%. The coverage includes investment trends, regulatory impact affecting nearly 42% of manufacturers, and technological advancements influencing 35% of production upgrades. Detailed insights into procurement strategies, hospital adoption rates exceeding 40% in developed regions, and innovation pipelines covering 30% of product portfolios are comprehensively evaluated.